These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 29462230

  • 1. Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
    Kuang AW, DuBois J, Attar M, Ahluwalia G.
    J Drugs Dermatol; 2018 Feb 01; 17(2):213-220. PubMed ID: 29462230
    [Abstract] [Full Text] [Related]

  • 2. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
    Baumann L, Goldberg DJ, Stein Gold L, Tanghetti EA, Lain E, Kaufman J, Weng E, Berk DR, Ahluwalia G.
    J Drugs Dermatol; 2018 Mar 01; 17(3):290-298. PubMed ID: 29537447
    [Abstract] [Full Text] [Related]

  • 3. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
    Kircik LH, DuBois J, Draelos ZD, Werschler P, Grande K, Cook-Bolden FE, Weng E, Berk DR, Ahluwalia G.
    J Drugs Dermatol; 2018 Jan 01; 17(1):97-105. PubMed ID: 29320594
    [Abstract] [Full Text] [Related]

  • 4. Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea.
    DuBois J, Dover JS, Jones TM, Weiss RA, Berk DR, Ahluwalia G.
    J Drugs Dermatol; 2018 Mar 01; 17(3):308-316. PubMed ID: 29537449
    [Abstract] [Full Text] [Related]

  • 5. Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.
    Tanghetti EA, Dover JS, Goldberg DJ, Dhawan SS, Luo L, Berk DR, Ahluwalia G, Alvandi N.
    J Drugs Dermatol; 2018 Jun 01; 17(6):621-626. PubMed ID: 29879249
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
    Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, Kempers SE, Alvandi N, Weng E, Berk DR, Ahluwalia G.
    J Am Acad Dermatol; 2018 Jun 01; 78(6):1156-1163. PubMed ID: 29409914
    [Abstract] [Full Text] [Related]

  • 7. Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study.
    Eichenfield LF, Del Rosso JQ, Tan JKL, Hebert AA, Webster GF, Harper J, Baldwin HE, Kircik LH, Stein-Gold L, Kaoukhov A, Alvandi N.
    Br J Dermatol; 2019 May 01; 180(5):1050-1057. PubMed ID: 30500065
    [Abstract] [Full Text] [Related]

  • 8. Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials.
    Stein-Gold L, Kircik L, Draelos ZD, Werschler P, DuBois J, Lain E, Baumann L, Goldberg D, Kaufman J, Tanghetti E, Ahluwalia G, Alvandi N, Weng E, Berk D.
    J Drugs Dermatol; 2018 Nov 01; 17(11):1201-1208. PubMed ID: 30500142
    [Abstract] [Full Text] [Related]

  • 9. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
    Patel NU, Shukla S, Zaki J, Feldman SR.
    Expert Rev Clin Pharmacol; 2017 Oct 01; 10(10):1049-1054. PubMed ID: 28837365
    [Abstract] [Full Text] [Related]

  • 10. Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea.
    Hoover RM, Erramouspe J.
    Ann Pharmacother; 2018 Mar 01; 52(3):263-267. PubMed ID: 29094614
    [Abstract] [Full Text] [Related]

  • 11. Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment.
    Gold MH, Lebwohl M, Biesman BS, Robinson DM, Luo L, Berk DR, Ahluwalia G, Alvandi N.
    J Am Acad Dermatol; 2018 Sep 01; 79(3):e57-e59. PubMed ID: 29860043
    [No Abstract] [Full Text] [Related]

  • 12. Oxymetazoline Hydrochloride 1% Cream (Rhofade) for Persistent Facial Erythema Associated with Rosacea.
    Garcia C, Birch M.
    Am Fam Physician; 2018 Jun 15; 97(12):808-810. PubMed ID: 30216014
    [No Abstract] [Full Text] [Related]

  • 13. Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study.
    Tanghetti EA, Goldberg DJ, Dover JS, Geronemus RG, Bai Z, Alvandi N, Shanler SD.
    Lasers Surg Med; 2021 Jan 15; 53(1):55-65. PubMed ID: 32378241
    [Abstract] [Full Text] [Related]

  • 14. Topical Oxymetazoline Hydrochloride Cream 1% for the Treatment of Persistent Facial Erythema of Rosacea in Adults: A Comprehensive Review of Current Evidence.
    Del Rosso JQ, Tanghetti E.
    J Clin Aesthet Dermatol; 2021 Mar 15; 14(3):32-37. PubMed ID: 33841614
    [Abstract] [Full Text] [Related]

  • 15. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
    Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M, Brimonidine Phase II Study Group.
    Br J Dermatol; 2012 Mar 15; 166(3):633-41. PubMed ID: 22050040
    [Abstract] [Full Text] [Related]

  • 16. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea.
    Dahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD.
    J Am Acad Dermatol; 2001 Nov 15; 45(5):723-30. PubMed ID: 11606923
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
    Fowler J, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M.
    J Drugs Dermatol; 2013 Jun 01; 12(6):650-6. PubMed ID: 23839181
    [Abstract] [Full Text] [Related]

  • 18. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
    Benkali K, Leoni M, Rony F, Bouer R, Fernando A, Graeber M, Wagner N.
    Br J Dermatol; 2014 Jul 01; 171(1):162-9. PubMed ID: 24506775
    [Abstract] [Full Text] [Related]

  • 19. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.
    Gold LS, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, Kerrouche N.
    J Drugs Dermatol; 2017 Sep 01; 16(9):909-916. PubMed ID: 28915286
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
    Moore A, Kempers S, Murakawa G, Weiss J, Tauscher A, Swinyer L, Liu H, Leoni M.
    J Drugs Dermatol; 2014 Jan 01; 13(1):56-61. PubMed ID: 24385120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.